BeiGene
BGNE
#1177
Rank
$13.43 B
Marketcap
$122.99
Share price
-9.01%
Change (1 day)
-64.14%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2022 (TTM): -$1.96 B

According to BeiGene 's latest financial reports the company's current earnings (TTM) are -$1.96 B. In 2021 the company made an earning of -$1.44 B an increase over its 2020 earnings that were of -$1.66 B. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.

Earnings history for BeiGene from 2015 to 2022

Year Earnings Change
2022 (TTM)-$1.96 B35.69%
2021-$1.44 B-13.21%
2020-$1.66 B72.69%
2019-$0.96 B36.01%
2018-$0.71 B616.83%
2017-$0.1 B-15.89%
2016-$0.12 B109.51%
2015-$0.06 B